ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies August 3, 2017
ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017 June 1, 2017
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia May 25, 2017
ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) April 19, 2017
